VANCOUVER, Feb. 24 /CNW/ - Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins for the treatment of prostate disease and other forms of cancer, today announced that Dr. Samuel Denmeade, Chief Scientific Officer at Protox, will be a speaker at the Third International Symposium on Focal Therapy and Imaging of Prostate and Kidney Cancer.
The symposium is being held at the Fairmont Hotel in Washington, D.C. from February 24th to 27th and will feature international experts who will provide insight into image-guided diagnosis and minimally invasive focal, gland-preserving treatment of prostate and kidney cancer. Dr Denmeade's talk entitled "PRX302: A Targeted PSA-activated Pore Forming Toxin for the Treatment of Benign and Malignant Diseases of the Prostate" will be presented on Friday, February 26, 2010.
"Prostate cancer affects 500,000 men around the world every year. Incidence is increasing due to the fact that lower risk cancers are detected at an earlier stage in younger men, many of whom undergo treatment which may be of unclear benefit in terms of life expectancy and may subject them to considerable morbidity," said Dr. Fahar Merchant, President and CEO of Protox. "Current approaches such as surgery and radiotherapy carry significant side effects such as incontinence, impotence and rectal problems because they treat the whole prostate and consequently damage surrounding structures in most men. Protox's PSA-activated PRX302 uses a pinpointed new approach called focal therapy, which can be effective in targeting only the cancerous portion of the prostate, avoiding collateral damage to tissues surrounding the prostate gland."
Protox Therapeutics is a leader in advancing novel, receptor targeted fusion proteins. Two novel drug candidates derived from the company's INxin(TM) and PORxin(TM) platforms are being developed in three clinical programs. Protox's lead program, PRX302 (PORxin), has announced positive results from its Phase 2b placebo controlled trial called TRIUMPH, to treat benign prostatic hyperplasia (BPH or enlarged prostate). In addition to these positive results, data from the Phase 2a study demonstrated durability at 12 months. PRX302 is also being evaluated for the treatment of localized prostate cancer. A Phase 2a clinical trial evaluating PRX321 (INxin) for the treatment of primary brain cancer has been completed and the drug has received Fast Track Designation and Orphan Drug Status from the US FDA and EMEA. Protox is also collaborating with the U.S. National Institutes of Health (NIH) on a research program focused on the discovery of next generation fully human targeted therapeutics.
Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Protox' current beliefs as well as assumptions made by and information currently available to Protox and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Protox in its public securities filings; actual events may differ materially from current expectations. Protox disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Sophiris Bio, Inc.
For further information: For further information: James Beesley, Senior Director, Investor Relations, Protox Therapeutics, (604) 484-0975, firstname.lastname@example.org; Michael Moore, Investor Relations, Equicom Group, (416) 815-0700 x 241, email@example.com